INTRODUCTION OF CENTRALIZED INR CONTROL IN KUZBASS
https://doi.org/10.17802/2306-1278-2016-2-105-110
Abstract
Purpose. Warfarin, an indirect anticoagulant, is commonly prescribed to patients who are at high risk for thrombotic complications. The achieved target hypocoagulation range allows to prevent thrombotic and hemorrhagic complications. Centralized international normalized ratio (INR) control increases the time in therapeutic range, improves quality control, reduces the rate of hospitalizations for bleeding and thromboembolism, suggesting its economic efficiency and allows to recommend this method of INR control for practical use. The current article presents the rationale for implementing centralized IRN control in the Kuzbass region in order to improve the efficiency and safety of ACT.
About the Authors
E. V. Gorbunova
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases. Kemerovo, Russia
Russian Federation
Russian Federation
Address: 6, Sosnoviy blvd., Kemerovo, 650002, Russian Federation Tel. +7 (3842) 34-17-26
S. A. Makarov
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases. Kemerovo, Russia
Russian Federation
Russian Federation
O. L. Barbarash
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases. Kemerovo, Russia
Russian Federation
Russian Federation
References
1. Wautrecht J. C. New developments in antithrombotic care. Rev. Med. Brux. 2009; 30 (4): 392–398.
2. Jones M., McEwan P., Morgan C. L., Peters J. R., Goodfellow J., Currie C. J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005; 91 (4): 472–477.
3. Лечение оральными антикоагулянтами. Методические рекомендации. М.: ГОУ ВПО «МГМСУ РОСЗДРАВА»; ГОУ ВПО «ММА им. И. М. Сеченова»; 2009: 48 с. Lechenie oral’nymi antikoagulyantami. Metodicheskie rekomendatsii. Moskow: GOU VPO «MGMSU ROSZDRAVA », M.GOUVPO «MMA im. I.M. Sechenova»; 2009: 48 s.
4. Kong M. C., Lim T. G., Ng H. J., Chan Y. H., Lee L. H. Feasibility, cost-effectiveness and patients› acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. Ann. Hematol. 2008; 87 (11): 905–910.
5. Garcia-Alamino J. M., Ward A. M., Alonso-Coello P., Perera R., Bankhead C., Fitzmaurice D. et al. Self-monitoring and selfmanagement of oral anticoagulation. Cochrane Database of Systematic Reviews. 2010, Issue 4. DOI: 10.1002/14651858. CD003839.pub2.
6. Затейщиков Д. А., Исаева М. Ю. Вопросы организации лечения антикоагулянтами. Клиническая практика. 2012; 3: 51–62. Zateyshchikov D. A., Isaeva M. Yu. Voprosy organizatsii lecheniya antikoagulyantami. Klinicheskaya praktika. 2012; 3: 51–62.
7. White H. D., Gruber M., Feyzi J., Kaatz S., DO, Tse H. F. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch. Intern. Med. 2007; 167: 239–245.
8. Сычев Д. А., Гаврисюк Е. В., Поликарпова О. А. Методология создания и функционирования центров персонализированной антикоагулянтной терапии: взаимодействие лабораторных и клинических методов повышения эффективности и безопасности фармакотерапии. Справ. зав. КДЛ. 2011; 10: 5–12. Sychev D. A., Gavrisyuk E. V., Polikarpova O. A. Metodologiya sozdaniya i funktsionirovaniya tsentrov personalizirovannoy antikoagulyantnoy terapii: vzaimodeystvie laboratornykh i klinicheskikh metodov povysheniya effektivnosti i bezopasnosti farmakoterapii. Sprav. zav. KDL. 2011; 10: 5–12.
9. Хруслов М. В., Лобачев В. И., Уханова И. Ю., Синицын А. А., Савчук О. Ф. Оценка экономической эффективности системы централизованного мониторинга пациентов, принимающих непрямые антикоагулянты. Поликлиника: спецвыпуск. 2014; 5: 7–10. Khruslov M. V., Lobachev V. I., Ukhanova I. Yu., Sinitsyn A. A., Savchuk O. F. Otsenka ekonomicheskoy effektivnosti sistemy tsentralizovannogo monitoringa patsientov, prinimayushchikh nepryamye antikoagulyanty. Poliklinika: spetsvypusk. 2014; 5: 7–10.
10. Clarkesmith D. E., Pattison H. M., Lane D. A. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst. Rev. 2013; 4: 6.
11. Tompson A., Heneghan C., Fitzmaurice D., Sutton S., Harrison S., Ward A. Supporting patients to self-monitor their oral anticoagulation therapy: recommendations based on a qualitative study of patients› experiences. Br. J. Gen. Pract. 2015; 65 (636): 438–446.
12. Christensen T. D. Self-management of oral anticoagulation therapy – methodological and clinical aspects. Dan. Med. Bull. 2011; 58 (5): 4284.
13. Wong Y. M., Quek Y. N., Tay J. C., Chadachan V., Lee H. K. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration. J. Clin. Pharm. Ther. 2011; 36 (5): 585–591. DOI: 10.1111/j.1365-2710.2010.01216.x.
14. Thompson J. L., Sundt T. M., Sarano M. E., Santrach P. J., Schaff H. V. Guidelines for self-controlling of international normalized ratio after mechanical heart valve implantation. Ann. Thorac. Surg. 2008; 85: 2046–2050. DOI: 10.1016/j.athoracsur.2008.01.051.
15. Koerfer R., Reiss N., Koertke H. International normalized ratio patient self-management for mechanical valves: is it safe enough? Curr. Opin. Cardiol. 2009; 24 (2): 130–135.
16. Eitz T., Schenk S., Fritzsche D., Bairaktaris A., Wagner O., Koertke H. et al. Self-control of international normalized ratio helps reduce the risk of thromboembolic complications after heart valve replacement. Ann. Thorac. Surg. 2008; 85: 949–955.
17. Christensen T. D., Larsen T. B. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. 2012; 10 (2): 251–260.
18. Dauphin C., Legault B., Jaffeux P., Motreff P., Azarnoush K., Joly H. et al. Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients. Arch. Cardiovasc. Dis. 2008; 101 (11–12): 753–761.
19. Gorter J. W. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999; 53: 1319–1327.
20. Козлова Т. В., Таратута Т. В. Возможности оптимизации антикоагулянтной терапии варфарином. Русский медицинский журнал. 2008; 11: 1532–1536. Kozlova T. V., Taratuta T. V. Vozmozhnosti optimizatsii antikoagulyantnoy terapii Varfarinom. Russkiy meditsinskiy zhurnal. 2008; 11: 1532–1536.
21. Колбин А. С., Вилюм И. А., Проскурин М. А., Балыкина Ю. Е. Фармакоэкономический анализ применения низкомолекулярных гепаринов для профилактики венозных тромбоэмболических осложнений в условиях многопрофильного стационара. Фармакоэкономика. 2013; 4 (6): 26–34. Kolbin A. S., Vilyum I. A., Proskurin M. A., Balykina Yu. E. Farmakoekonomicheskiy analiz primeneniya nizkomolekulyarnykh geparinov dlya profilaktiki venoznykh tromboembolicheskikh oslozhneniy v usloviyakh mnogoprofil’nogo statsionara. Farmakoekonomika. 2013; 4 (6): 26–34.
22. Дземешкевич С. Л., Панченко Е. П. Антикоагулянтная терапия у пациентов с клапанными пороками сердца. Русский медицинский журнал. 2001; 10: 427–430. Dzemeshkevich S. L., Panchenko E. P. Antikoagulyantnaya terapiya u patsientov s klapannymi porokami serdtsa. Russkiy meditsinskiy zhurnal. 2001; 10: 427–430.
23. Национальные рекомендации по ведению, диагностике и лечению клапанных пороков сердца. М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН; 2009: 356 с. Natsional’nye rekomendatsii po vedeniyu, diagnostike i lecheniyu klapannykh porokov serdtsa. Moskow: Izd-vo NTsSSKh im. A. N. Bakuleva RAMN; 2009: 356 s.
24. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857–867.
25. Ansell J., Hirsh J., Dalen J., Bussey H., Anderson D., Poller L. et al. Managing oral anticoagulant therapy. Chest. 2001; 119 (1): 22–38.
Review
For citations:
Gorbunova E.V., Makarov S.A., Barbarash O.L. INTRODUCTION OF CENTRALIZED INR CONTROL IN KUZBASS. Complex Issues of Cardiovascular Diseases. 2016;(2):105-110. (In Russ.) https://doi.org/10.17802/2306-1278-2016-2-105-110
Views:
614
